Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05851859 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of the Effectiveness of Breathing Control Technique on Long COVID Symptoms at the Reunion University Hospital

Study acronym: COCO-Long'Run
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Minor Re-verified, no change to tracked fieldsv6
  2. Notable Trial status: Not Yet Recruiting to Recruitingv5 Show 4 more changesShow less
    • Start date changed from estimate of Aug 1, 2024 to May 5, 2025
    • Primary completion date: Feb 1, 2027 to Nov 2026
    • Study completion date: Apr 1, 2027 to Apr 2027
    • Site details revised at 2 of 2 sites
  3. Notable Start date: Mar 29, 2024 to Aug 1, 2024
    • Primary completion date: Sep 1, 2026 to Feb 1, 2027
    • Study completion date: Nov 1, 2026 to Apr 1, 2027
    • Study title shortened, about 6 words
    v4
  4. Notable Start date: Oct 1, 2023 to Mar 29, 2024
    • Primary completion date: Apr 1, 2026 to Sep 1, 2026
    • Study completion date: Jun 1, 2026 to Nov 1, 2026
    v3
  5. Notable Start date: Aug 1, 2023 to Oct 1, 2023
    • Primary completion date: Feb 1, 2026 to Apr 1, 2026
    • Study completion date: Apr 1, 2026 to Jun 1, 2026
    • Study title expanded, about 1 word
    v2
  6. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Despite the controversy, on October 6, 2021, the World Health Organization (WHO) recognized Long Coronavirus disease (COVID) by officially defining it: " symptoms appeared 3 months after the onset of the primary infection by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), persisting for at least 2 months and which cannot be explained by any other condition ". Long COVID can affects any type of patient and has polymorphic and fluctuating symptoms over time. The Reunion Island is a French overseas department located in the Indian Ocean accounting more than 860,000 inhabitants. It has recorded since March 11, 2020, nearly 491,825 cases of COVID-19 and 961 deaths of hospitalized patients. Reunion's population is multi-ethnic and younger than the metropolitan France's one. It also has a higher prevalence of obesity and type 2 diabetes, two serious form factors of COVID-19. This specific context makes this island a particular study site for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Long COVID. In addition, some studies have confirmed the involvement of the autonomic nervous system (ANS) in the symptomatology of Long COVID and demonstrated that patients with a Long COVID present a dysfunction of their ANS which is objectified by a reduced Heart Rate Variability (HRV). The regulation of heart rate by the ANS is strongly favored by respiration. A regular slow and deep breathing training helps to adjust the baroreflex, which connect heart rate, breathing and blood pressure. The result of this training is an induced state called "cardiac coherence" (CC). The investigator therefore hypothesize that respiratory training to CC could "re-educate" the ANS and durably improve the symptomatology of patients with Long COVID.
Trial Details
NCT Number NCT05851859
Lead Sponsor Centre Hospitalier Universitaire de la Réunion
Conditions
(from sponsor)
Long COVID
Related terms Post-Acute COVID-19 Syndrome
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov